Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sobi, Inc.

Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
From Sobi, Inc.
Via GlobeNewswire
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
From Sobi, Inc.
Via GlobeNewswire
Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia
From Sobi, Inc.
Via GlobeNewswire
Sobi to present new data across its immunology portfolio at the ACR Convergence 2024
From Sobi, Inc.
Via GlobeNewswire
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
From Sobi, Inc.
Via GlobeNewswire
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
From Sobi, Inc.
Via GlobeNewswire
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
From Sobi, Inc.
Via GlobeNewswire
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
From Sobi, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.